The trial is designed to assess the therapy's efficacy when administered subcutaneously in single ascending doses.

Those that know, know: Atopic dermatitis, otherwise known as eczema, is no walk in the park—especially for Black folks. According to the National Eczema Association, African Americans are more likely ...

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2. All three cohorts show separation from placebo ...

Investors were surely discovering drug discovery company AbCellera Biologics ( ABCL 6.19%) as the trading week kicked off on ...

Mumbai: Sun Pharmaceutical Industries Limited has announced the discontinuation of two clinical trials evaluating SCD-044, a ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

Sun Pharma’s phase 2 trials of SCD-044 to treat moderate to severe psoriasis and atopic dermatitis fails to meet primary endpoint: Our Bureau, Mumbai Wednesday, June 4, 2025, 11 ...

Anti-OX40 medications have been associated with positive efficacy and safety outcomes for the treatment of atopic dermatitis.